exciting morning for our team at MSK’s digital pathology course! learning a lot about potentially transformative technologies in oncology Memorial Sloan Kettering Biostatistics Service MSK CME

congratulations ⁦⁦Sandra P D'Angelo, MD⁩ and colleagues on this landmark trial! an exciting time for cellular therapies across solid tumors thelancet.com/journals/lance…

In medicine we don’t say “I love you” we say “that’s not unreasonable” and I think that’s beautiful

big day in solid tumor oncology-- lifileucel has gained FDA approval as the first cellular therapy for melanoma!! excited for more patients to have access to TIL soon, and to build on this milestone going forward ASTCT Melanoma Research Foundation AIM at Melanoma Foundation Memorial Sloan Kettering Cancer Center

i may have lost to the 🐯, but such an honor to debate Allison Betof Warner, MD, PhD at Melanoma Bridge 2023! blown away by all the speakers and the exciting progress in our field Alex Shoushtari, MD Michael Postow Puig-Saus Lab Paolo A. Ascierto Simone Krebs

It’s not that minority patients aren’t interested (to enroll in clinical trials):
“If you’re never invited, you can’t take interest. If you’re never educated, you can’t take interest.“ Dr. Lucille Adams-Campbell Georgetown University Georgetown Lombardi Memorial Sloan Kettering Cancer Center
#mskhealthequityCME

Thank you Memorial Sloan Kettering Cancer Center for this incredible honor of the 2023 Paul Marks Prize! I am grateful to receive this alongside two other brilliant investigators and friends. My teams will continue on our mission to advance novel biology to new medicines for patients with #cancer .

really impressed by the biologically-informed dose finding & promising peripheral ctDNA signal in this presentation - more therapeutic options urgently needed for uveal melanoma!

good morning san diego! excited for great science and connecting with colleagues at #SITC23

Exciting work at ESMO - Eur. Oncology 2023 by Róisín O’Cearbhaill sharing results from the phase 1 study of a novel bispecific antibody in combination with cemiplimab for patients with recurrent ovarian cancer showing durable responses in a subset of patients. MSKCC Team Uterus Team Ovary, Memorial Sloan Kettering Cancer Center

way to go Sarah E. Lochrin! not sure but i think you may have spelled melanoma wrong?? 🙃

Update in #melanoma #TIL news: lifileucel PDUFA date pushed back to Feb 2024 due to delays on the FDA Oncology end. This isn’t a problem with the data etc.

This is a huge hit to patients desperately waiting for this lifesaving treatment. We already have waitlists and now there…

Join me on Oct. 13 for the Society for Immunotherapy of Cancer #LearnACI live hybrid MSI-high/TMB-high Cancers & Biomarkers program featuring in-depth education from a panel of experts. Register and invite a colleague: sitcancer.org/education/aci/…

📢 Inviting Cardiology 🫀 fellows - join us at @sloan_kettering as #cardioonc fellows in 2024! Exciting opportunity in NYC 🗽
Research 🔬🧪, clinical, and advanced imaging training!
💯 grads land academic leadership roles. DM for details. Please RT #CardioTwitter

thank you Michael Postow!! im beyond excited to work with you, Alex Shoushtari, MD and the rest of this incredible group

so grateful to have shared an office with these amazing & brilliant colleagues this year! will be cheering on all your accomplishments in the years ahead 💊🔬🇺🇸🌎🇮🇪 Kelly Fitzgerald Fergus Keane Emily Harrold

It’s finally #MelanomaMonday at #ASCO23 ! Come join us at 3pm in Hall D1 for the melanoma oral abstract session. Exciting data to come today from my colleagues Hussein Tawbi, MD, PhD Omid Hamid MD Zeynep Eroglu Jason Luke, MD, FACP Professor Georgina Long AO et al. OncoAlert